SML3647
Ulifloxacin
≥98% (HPLC)
Synonym(s):
6-Fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-1H,4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid, AF 3013, NAD 394, NM 394
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C16H16FN3O3S
CAS Number:
Molecular Weight:
349.38
UNSPSC Code:
51111800
NACRES:
NA.77
MDL number:
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
Fc1cc2c(cc1N4CCNCC4)N3C(SC3=C(C2=O)C(=O)O)C
InChI
1S/C16H16FN3O3S/c1-8-20-11-7-12(19-4-2-18-3-5-19)10(17)6-9(11)14(21)13(16(22)23)15(20)24-8/h6-8,18H,2-5H2,1H3,(H,22,23)
InChI key
SUXQDLLXIBLQHW-UHFFFAOYSA-N
Biochem/physiol Actions
Orally available, broad-spectrum fluoroquinolone antibacterial agent that potently inhibits bacterial DNA gyrase and topoisomerase IV
Ulifloxacin is an orally available, broad-spectrum fluoroquinolone antibacterial agent. Ulifloxacin is an active metabolite of Prulifloxacin. It potently inhibits bacterial DNA gyrase and topoisomerase IV.
signalword
Warning
hcodes
Hazard Classifications
Lact. - Skin Irrit. 2 - STOT RE 2
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Susan J Keam et al.
Drugs, 64(19), 2221-2234 (2004-10-01)
Prulifloxacin, the prodrug of ulifloxacin, is a broad-spectrum oral fluoroquinolone antibacterial agent. After absorption, prulifloxacin is metabolised by esterases to ulifloxacin. The drug has a long elimination half-life, allowing once-daily administration. Ulifloxacin is generally more active in vitro than other
Valeria Tellone et al.
Drugs in R&D, 18(3), 237-245 (2018-08-29)
The antibacterial agent prulifloxacin, a prodrug of ulifloxacin, is indicated in the treatment of acute lower urinary tract infections, acute exacerbation of chronic bronchitis and acute bacterial rhinosinusitis. We aimed to provide new insights on the pharmacokinetics (PK) of ulifloxacin
Marcello Locatelli et al.
Journal of enzyme inhibition and medicinal chemistry, 31(1), 106-111 (2015-02-17)
A new and specific HPLC-DAD method for the direct determination of Prulifloxacin and its active metabolite, Ulifloxacin, in human plasma has been developed. Plasma samples were analysed after a simple solid phase extraction (SPE) clean-up using a new HILIC stationary
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML3647-10MG | 04065269791799 |
| SML3647-50MG | 04065269791805 |